Roche: experimental drug fails in Alzheimer study
(CercleFinance.com) - An investigational medicine from Roche has failed to show a significant slowing of the rate of cognitive decline in people with a rare inherited form of Alzheimer's disease, the Swiss drugmaker said on Monday.
Roche's gantenerumab arm in a Phase II/III study did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer's disease, which represents under 1% of all the disease's cases.
The study, sponsored by Washington University School of Medicine in St. Louis, US, did not show a significant slowing of the rate of cognitive decline in people treated with the medicine, compared with placebo, it said
Despite this setback, Roche plans to conduct additional analyses to understand all the data, which will be presented at a meeting in April.
Given its experimental nature, the study does not reduce Roche's confidence in the ongoing Phase III clinical trial, the group said.
Roche shares were down 0.8% this morning in a slightly weaker market for European pharmaceutical stocks.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Roche's gantenerumab arm in a Phase II/III study did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer's disease, which represents under 1% of all the disease's cases.
The study, sponsored by Washington University School of Medicine in St. Louis, US, did not show a significant slowing of the rate of cognitive decline in people treated with the medicine, compared with placebo, it said
Despite this setback, Roche plans to conduct additional analyses to understand all the data, which will be presented at a meeting in April.
Given its experimental nature, the study does not reduce Roche's confidence in the ongoing Phase III clinical trial, the group said.
Roche shares were down 0.8% this morning in a slightly weaker market for European pharmaceutical stocks.
Copyright (c) 2020 CercleFinance.com. All rights reserved.